The use of Escherichia coli total antigens as a complementary approach to address seropositivity to Leishmania antigens in canine leishmaniosis
| Autor: | Luís Cardoso, João R. Mesquita, Ana Rafaela Teixeira, Nuno Santarém, Anabela Cordeiro da Silva, Hugo Brancal, Célia G. Amorim, Carla Lima, Thomas W. Vahlenkamp |
|---|---|
| Přispěvatelé: | Instituto de Investigação e Inovação em Saúde |
| Rok vydání: | 2017 |
| Předmět: |
Protozoan Proteins
Recombinant Proteins/blood Serology law.invention 0403 veterinary science 0302 clinical medicine law Protozoan Proteins/blood Antigens Bacterial/blood Dog Diseases Leishmania infantum Adenosine Triphosphatases SEC Translocation Channels/blood Dog Diseases/diagnosis biology Leishmaniasis Visceral/diagnosis Leishmania infantum/isolation & purification 04 agricultural and veterinary sciences Dog Diseases/immunology Recombinant Proteins 3. Good health Infectious Diseases Cohort Recombinant DNA Leishmaniasis Visceral Enzyme-Linked Immunosorbent Assay/veterinary 040301 veterinary sciences 030231 tropical medicine Antigens Protozoan Enzyme-Linked Immunosorbent Assay Sensitivity and Specificity 03 medical and health sciences Dogs Bacterial Proteins Antigen parasitic diseases Escherichia coli medicine Animals Adenosine Triphosphatases/blood Bacterial Proteins/blood Antigens Bacterial SecA Proteins Escherichia coli/immunology Portugal Leishmaniasis Antigens Protozoan/blood biology.organism_classification Leishmania medicine.disease Virology Leishmaniasis Visceral/immunology Parasitology Immunology Animal Science and Zoology Leishmaniasis Visceral/veterinary SEC Translocation Channels |
| Zdroj: | Repositório Científico de Acesso Aberto de Portugal Repositório Científico de Acesso Aberto de Portugal (RCAAP) instacron:RCAAP |
| ISSN: | 1469-8161 0031-1820 |
| Popis: | Canine leishmaniosis (CanL) is a major veterinary concern and a public health issue. Serological data are essential for disease management. Several antigens used in serological assays have specificity related problems preventing relevant seropositivity values establishment. Herein we report significant seropositivity level disparity in a study cohort with 384 dogs from eight countries, for antigens traditionally used in CanL - soluble promastigote Leishmania antigens (SPLA) and K39 recombinant protein (rK39): 43·8 and 2·9% for SPLA and rK39, respectively. To better understand the reasons for this disparity, CanL-associated serological response was characterized using, for complement serological evaluation, a ubiquitous antigen - soluble Escherichia coli antigens (SECAs). Using cohorts of CanL dogs and dogs without clinical evidences of CanL from non-endemic regions of Portugal, the serological response of CanL animals followed specific trend of seropositivity rK39 > SPLA > SECA absent in non-diseased animals. Using receiver operating characteristic curve analysis, these characteristic trends were converted in ratios, SPLA/SECA, rK39/SECA and rK39/SPLA, that presented high predictive for discriminating the CanL cohort that was potentiated when applied in a scoring system involving positivity to four out of five predictors (rK39, SPLA, SPLA/SECA, rK39/SECA and rK39/SPLA). In fact, this approach discriminated CanL with similar sensitivity/specificity as reference antigens, diminishing seropositivity in European cohort to 1·8%. Ultimately, non-related antigens like SECA and seropositivity ratios between antigens enable different perspectives into serological data focusing on the search of characteristic serological signatures and not simple absolute serology values contributing to comprehensive serological status characterization. This work was financed by FEDER–Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020–Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through FCT Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior in the framework of the project‘Institute for Research and Innovation in Health Sciences’(POCI-01-0145-FEDER-007274) and from the European Community’s Seventh Framework Programme under grant agreement No. 603181 [Clinical Studies on a Multivalent Vaccine for Human Visceral Leishmaniasis (MuLeVaClin)]. ‘This article is a result of the project NORTE-01-0145-FEDER-000012, supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF)’. C.L. and N.S. were supported by BD SFRH/BD/89183/2012 and European Community’s Seventh Framework Programme under grant agreement No. 602773 (Project KINDRED), respectively. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|